Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies, AŞ Message Board

beepoe111 18 posts  |  Last Activity: Jun 24, 2015 6:27 PM Member since: Dec 12, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Acquiring today a good thing, Disposing Tomorrow? Time will Tell.....
    Time to back up the truck if

    Sentiment: Hold

  • Reply to

    optimization plan

    by hosaquavos Jun 12, 2015 12:02 PM
    beepoe111 beepoe111 Jun 15, 2015 5:24 PM Flag

    Ahhhh More Like GangRaped Shareholder Syndrome.....

    Sentiment: Hold

  • beepoe111 beepoe111 Jun 10, 2015 10:13 PM Flag

    Look at the forms Again and the shares owned before and after these are exercising options. they are D'ing options and A'ing direct ownership shares. this was forecasted a year+ ago when they were awarded these options for doing "Such a Great Job!"sic

    Sentiment: Hold

  • Reply to

    Shareholder secret meeting, seriously?!?!

    by drod4ball Jun 6, 2015 8:10 PM
    beepoe111 beepoe111 Jun 8, 2015 6:30 PM Flag

    You can also go back about 3 yrs and will find info on the expiration maturation dates of the Options awarded to "the Chosen Few"

    Sentiment: Hold

  • Reply to

    Shareholder secret meeting, seriously?!?!

    by drod4ball Jun 6, 2015 8:10 PM
    beepoe111 beepoe111 Jun 8, 2015 6:27 PM Flag

    Ya I heard about a month before the mtg, go to the siga site / investor relations and sign up for the notices. It was also sent in a message on my E-trade account I believe.....

    Sentiment: Hold

  • beepoe111 beepoe111 Jun 8, 2015 5:54 PM Flag

    I got these notices Friday as they were released, to do so go to the Siga site / investor relations and sign up for notices.

    Sentiment: Hold

  • Reply to

    Tax purposes Really???

    by beepoe111 Jun 4, 2015 7:07 PM
    beepoe111 beepoe111 Jun 5, 2015 5:36 PM Flag

    This Form 4 reports the sale by the Reporting Person of 40,000 shares of Common Stock, which shares of Common Stock were sold to raise the funds required to satisfy such withholding tax obligations. Et tu, Hurby?

    Sentiment: Hold

  • This Form 4 reports the sale by the Reporting Person of 25,000 shares of Common Stock, which shares of Common Stock were sold to raise the funds required to satisfy such withholding tax obligations. Way to Go Rose....

    Sentiment: Hold

  • Reply to

    Form 25 Filling

    by beepoe111 May 26, 2015 11:17 PM
    beepoe111 beepoe111 Jun 1, 2015 7:06 PM Flag

    Oh Wait I see that was Options Expiration 6/2 executed on 5/28 Ya I see's it now....Nothing to see here Move along Move along........

    Sentiment: Hold

  • Reply to

    Form 25 Filling

    by beepoe111 May 26, 2015 11:17 PM
    beepoe111 beepoe111 Jun 1, 2015 7:03 PM Flag

    Well guess it is still trading.......
    But 7k? what happened to the 10k Antal Dumped???

    Sentiment: Hold

  • Reply to

    Form 25 Filling

    by beepoe111 May 26, 2015 11:17 PM
    beepoe111 beepoe111 May 27, 2015 6:11 PM Flag

    Beuller? Anyone?? anyone Beuller??

    Sentiment: Hold

  • beepoe111 by beepoe111 May 26, 2015 11:17 PM Flag

    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Delisting Determination, The Nasdaq Stock Market, LLC, May 21, 2015, SIGA Technologies Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock of SIGA Technologies Inc. (the Company), effective at the opening of the trading session on June 1, 2015. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5110(b).
    The Company was notified of the Staffs
    determination on September 16, 2014. The Company appealed the determination to a Hearing Panel.
    Upon review of the information provided by the Company, the Panel issued a decision dated October 29, 2014, granting the Company continued listing pursuant to an exception that included several milestones that the Company was required to meet, towards the goal of regaining compliance with Listing Rule 5110(b).
    However, the Company was unable to meet the exception milestones as required. On March 18, 2015, the Panel issued a final delisting determination and notified the Company that trading in the Company's securities would be suspended on March 20, 2015. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on May 4, 2015.

    So this is 2 months old Paperwork right????
    Still be trading SIGAQ on the PK's????

    Sentiment: Hold

  • Reply to

    100M Tax payers money for what????

    by beepoe111 Apr 20, 2015 7:47 PM
    beepoe111 beepoe111 Apr 29, 2015 6:59 PM Flag

    (VARV; the causative agent of smallpox), a model for smallpox disease in humans. Following challenge, 50% of placebo-treated controls succumbed to infection, while all tecovirimat-treated animals survived regardless of whether treatment was started at 2 or 4 days postinfection. In addition, tecovirimat treatment resulted in dramatic reductions in dermal lesion counts, oropharyngeal virus shedding, and viral DNA circulating in the blood. Although clinical disease was evident in tecovirimat-treated animals, it was generally very mild and appeared to resolve earlier than in placebo-treated controls that survived infection. Tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox-infected humans.

  • Reply to

    100M Tax payers money for what????

    by beepoe111 Apr 20, 2015 7:47 PM
    beepoe111 beepoe111 Apr 21, 2015 10:25 PM Flag

    just in case you were wondering what the Trial data for a Viable Smallpox cure looks like Read this:

    Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).

    Mucker EM1, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM, Holman RC, Carroll D, Gallardo N, Olson VA, Clemmons CJ, Hudson P, Hruby DE.

    Author information

    1United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, Maryland, USA.

    Abstract

    Naturally occurring smallpox has been eradicated but remains a considerable threat as a biowarfare/bioterrorist weapon (F. Fleck, Bull. World Health Organ. 81:917-918, 2003). While effective, the smallpox vaccine is currently not recommended for routine use in the general public due to safety concerns (http://www.bt.cdc.gov/agent/smallpox/vaccination). Safe and effective countermeasures, particularly those effective after exposure to smallpox, are needed. Currently, SIGA Technologies is developing the small-molecule oral drug, tecovirimat (previously known as ST-246), as a postexposure therapeutic treatment of orthopoxvirus disease, including smallpox. Tecovirimat has been shown to be efficacious in preventing lethal orthopoxviral disease in numerous animal models (G. Yang, D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, et al., J. Virol. 79:13139-13149, 2005; D. C. Quenelle, R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, et al., Antimicrob. Agents Chemother., 51:689-695, 2007; E. Sbrana, R. Jordan, D. E. Hruby, R. I. Mateo, S. Y. Xiao, et al., Am. J. Trop. Med. Hyg. 76:768-773, 2007). Furthermore, in clinical trials thus far, the drug appears to be safe, with a good pharmacokinetic profile. In this study, the efficacy of tecovirimat was evaluated in both a prelesional and postlesional setting in nonhuman primates challenged intravenously with 1 × 10(8) PFU of Variola virus (VARV; the causative agent of smallpox), a model for smallpox disease in humans. Following challenge, 50% of placebo-treated controls succumbed to infection, while all tecovirimat-treated animals survived regardless of whether treatment was started at 2 or 4 days postinfection. In addition, tecovirimat treatment resulted in dramatic reductions in dermal lesion counts, oropharyngeal virus shedding, and viral DNA circulating in the blood. Although clinical disease was evident in tecovirimat-treated animals, it was generally very mild and appeared to resolve earlier than in placebo-treated controls that survived infection. Tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox-infected humans.

  • Reply to

    100M Tax payers money for what????

    by beepoe111 Apr 20, 2015 7:47 PM
    beepoe111 beepoe111 Apr 21, 2015 7:26 PM Flag

    Go to clinicaltrials (dot) gov and what do you find a bunch of trials that have been completed with no results(Oh?? I wonder why that is???) or ones that have been withdrawn..... This Drug is a Placebo with a lot more downside than up AKA the only thing that this drug has been show to do is cause RENAL failure.

    Where oh where are the Results????

  • Reply to

    100M Tax payers money for what????

    by beepoe111 Apr 20, 2015 7:47 PM
    beepoe111 beepoe111 Apr 21, 2015 7:10 PM Flag

    Ya really? how about the one it is supposed to cure AKA Latent Stage Smallpox???... Not!!!!

  • Reply to

    100M Tax payers money for what????

    by beepoe111 Apr 20, 2015 7:47 PM
    beepoe111 beepoe111 Apr 20, 2015 11:51 PM Flag

    Oh it will save a few rabbits but primates Not!!!!!

    The Fact is Gforrbidd anyone should every have to really reach for this waste of cash, It ain't gonna do Squat for what it is intended for which is to Cure Symptomatic AKA late stage Smallpox.

    Brincidofovir+Monkeys+Smallpox= Dead Monkeys

  • Where is there any evidence that brincidofovir Cures Smallpox in either primates or humans???
    This an absolute waste of Taxpayers Money.

    brincidofovir + Smallpox = Dead Monkeys

SIGA
0.00(0.00%)